PERSEUS Trial Design and Overview
Brea C. Lipe, MD explains the trial design and patient population of PERSEUS phase three trial.
Summary
Brea C. Lipe, MD reviews the PERSEUS trial conducted by the European Myeloma Network. This trial was a phase three randomized trial of over 700 patients comparing a quadruplet regimen of lenalidomide, bortezomib, dexamethasone, and subcutaneous daratumumab (DARA) to a triplet without daratumumab (VRd) for 28-day cycles. After induction, patients went on to maintenance with lenalidomide and dexamethasone. Notably, patients in the Dara-VRd arm who were MRD negative for 12 consecutive months after 2 years maintenance were able to discontinue treatment. The trial demonstrated improved progression-free and overall survival with Dara-VRd compared to VRd. Recognizing these nuanced design and regimen details is important when interpreting the trial results and determining applicability.
Summary was AI-generated and edited for clarity.
Real-World RRMM Data Explore Dose Deescalation and Outpatient Use of Teclistamab
November 18th 2024During a Case-Based Roundtable® event, Hana Safah, MD, examined several real-world studies of dose frequency and outpatient administration of teclistamab in patients with multiple myeloma in the first article of a 2-part series.
Read More
